Amgen developed Maridebart Cafraglutide for obesity
It combines GIP receptor blockade and GLP-1 activation, potentially enabling monthly dosing. Phase 3 trials are ongoing.
See the latest news and media coverage for Amgen. We track all announcements, press releases, and industry mentions in real time, all in one place.
Multinational biopharmaceutical company
amgen.comLast updated
In short: Amgen reported strong first-quarter 2026 financial growth and significant pipeline progress while facing regulatory scrutiny over its drug Tavneos.
It combines GIP receptor blockade and GLP-1 activation, potentially enabling monthly dosing. Phase 3 trials are ongoing.
The South San Francisco facility integrates chemistry, biology, and data science using DMTA cycle to accelerate small molecule drug discovery.
This adds to nearly $2 billion invested over the last year, expanding Puerto Rico facility for biologics production and supply chain resilience. It supports jobs and next-generation technologies.
She receives top U.S. honor for immunology and oncology research impacting cancer immunotherapies. As VP of Research, she advances drug discovery.
Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.
The latest fair value estimate for Amgen has shifted slightly, from US$350.03 to US$349.66, keeping modeled upside closely aligned with prior assumptions. That small adjustment...
Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to pu...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may...
Track Amgen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Amgen and other trending companies.